United Kingdom: Invest in ME news

https://investinme.org/iimer-newslet-2511-yeworkshopgrants.shtml

Invest in ME Research is pleased to announce that it will be further supporting the Young EMERG group by providing grants to cover hotel expenses for some delegates attending the forthcoming Young EMERG International ME Workshop in Vienna.

The charity initiated the European ME Research Group (EMERG) young/early career researcher network - Young EMERG - to encourage and support new researchers into the field and to develop capacity.

To encourage and facilitate participation the award of accommodation grants has been made to applicants from around Europe.
This enables the delegates to fully participate in the event and meet other Young EMERG members.

Highlighting

Jordan McGing, Postdoctoral Research Assistant, University of Oxford, United Kingdom​

Jordan McGing is a Postdoctoral Research Assistant at the University of Oxford in the United Kingdom, specialising in metabolic imaging and the physiology of fatigue. As an early career researcher, he brings expertise from studies into fatigue aetiology, including recent work on muscle and metabolic function in chronic conditions such as Crohn’s disease and myalgic encephalomyelitis (ME).

Jordan has recently taken a leading role in the Valkolvic Group’s innovative project investigating the physiological mechanisms underlying post-exertional malaise (PEM) in ME, using advanced metabolic imaging and near-infrared spectroscopy to deepen understanding of skeletal muscle involvement in this condition.

See https://www.rdm.ox.ac.uk/people/jordan-mcging

First author of Magnetic Resonance Quantification of Muscle Phosphocreatine Resynthesis Kinetics During Exercise Recovery: An In Vivo Measure of Mitochondrial Function in Humans (2023)
 
[I thought this information had been posted on the forum but could not find it]


18th International ME Conference 2026
29 May 2026

The conference will commence at approximately 08:55 and will conclude at approximately 17:00 on 29 May.

Overview of event
20 Years of Investing in ME Research: Discover ME

The 18th International ME Conference (#IIMEC18), organised by Invest in ME Research, will take place on 29th May 2026 at the Wellcome Genome Campus, Hinxton Hall.

IIMEC18 will bring together a distinguished group of researchers, clinicians, and patient advocates to share knowledge and foster collaboration. As an additional day to the BRMEC15 Researchers' Colloquium, IIMEC18 will be open to the public, providing a unique opportunity for broader engagement with the latest developments in Myalgic Encephalomyelitis (ME) research.

While BRMEC15 is a closed event for researchers, IIMEC18 will allow patients, carers, and the general public to attend and contribute to discussions, making it an important step in bridging the gap between the scientific community and the wider ME population.

Agenda:

 
Last edited:
From a Bluesky post by Invest in ME:
International ME Conference Week Begins Tomorrow
Five full days dedicated to ME

Keynote speaker at #BRMEC15 - Professor Sarah Teichmann

International Conference Week 2026:

The International ME Conference Week events span five days and this year are arranged for 25 - 29 May 2026.

Working with the European ME Research Group (EMERG) and our international friends and contacts, we hope to have a very productive and informative international conference week of events to make progress in research into ME.

Across five days, ME Conference Week 2026 will comprise four research-focused events organised by the charity, bringing together researchers for detailed discussion of current evidence, methods and future directions in ME research.
 
I will be going and I am surprised to find one of the speakers is https://www.uab.edu/reporter/resear...ts-for-treatment-of-long-covid-with-brain-fog
Yeah, Professor Uswatte‘s study didn’t fare particularly well in the S4ME review:
Trial registration:
https://clinicaltrials.gov/study/NCT04644172

This is not very PEM-friendly.

Comparing the different versions:
  • They removed the only slightly objective outcome measure after they had completed the intervention:
  • They shortened the wait from six to three months, reducing the impact of the waitlist control.
  • They wanted to recruit 40 participants, but only got 14.

No, this was not a 'modest-sized' study. It was a tiny study, a study size that in no way justifies the claims made.
 
Back
Top Bottom